Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05120947 · ClinicalTrials.gov registry record · NA
Hypofractionated Adjuvant Radiotherapy for Resected Head and Neck Cancers
A NA study, sponsored by Medical College of Wisconsin.
- Completed
- Registry status
- NA
- Development phase
- 18
- Enrollment target
NCT05120947: Completed NA study, sponsored by Medical College of Wisconsin.
NCT05120947 is a NA study that has completed, run by Medical College of Wisconsin. The registered enrollment target is 18 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05120947, a NA study, has completed, sponsored by Medical College of Wisconsin.
- COMPLETED
- Registry status
- NA
- Development phase
- 18 participants
- Enrollment target
Study Summary
The primary purpose of this study is to determine the safe reduction of the treatment fractions to 10, 8, or 5, that may be delivered safely in resected head and neck squamous cell carcinoma (HNSCC) patients with intermediate pathologic risk features.
Primary Outcome
This will be determined as the radiation dose with the minimum number of fractions at which there is no more than a 33% rate of dose-limiting toxicity (DLT) up to 12 months after completion of radiation treatment using the TITE-CRM design.
Interventions
- RADIATION 42 Gy Radiation Therapy
- RADIATION 39 Gy Radiation Therapy
- RADIATION 32.5 Gy Radiation Therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2021-12-01 |
| Est. Completion | 2025-11-22 |
| Phase | NA |
What the finished NCT05120947 record still lists
NCT05120947 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 18 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 3 interventions - of which 42 Gy Radiation Therapy is the first listed.
NCT05120947 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05120947 about?
NCT05120947 is a clinical study titled "Hypofractionated Adjuvant Radiotherapy for Resected Head and Neck Cancers". The primary purpose of this study is to determine the safe reduction of the treatment fractions to 10, 8, or 5, that may be delivered safely in resected head and neck squamous cell carcinoma (HNSCC) patients with intermediate pathologic risk features.
What is the current status of trial NCT05120947?
This trial is currently completed. It is a NA study. The enrollment target is 18 participants. The study started on 2021-12-01. Estimated completion is 2025-11-22.
What interventions are being tested in trial NCT05120947?
The interventions under investigation include: 42 Gy Radiation Therapy (RADIATION), 39 Gy Radiation Therapy (RADIATION), 32.5 Gy Radiation Therapy (RADIATION).
Who is sponsoring clinical trial NCT05120947?
This trial is sponsored by Medical College of Wisconsin, which has 447 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05120947's enrollment target sits among peer trials
18 1863rd of 2000 higher than 130 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01245179 · 18 participants · Phase 1
Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease
- NCT01999361 · 18 participants · NA
Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss
- NCT02359825 · 18 participants · Phase 1
Nerve Repair Using Hydrophilic Polymers to Promote Immediate Fusion of Severed Axons and Swift Return of Function
- NCT02870244 · 18 participants · Phase 1
Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI